GeoVax Highlights MVA Platform's Potential Amid Bundibugyo Ebola Outbreak
GeoVax Labs comments on the WHO-declared PHEIC for Bundibugyo Ebola, emphasizing the need for flexible vaccine platforms like its MVA-based technology to address emerging viral threats.
GeoVax Labs (Nasdaq: GOVX) has weighed in on the escalating Bundibugyo Ebola virus (BDBV) outbreak in Central Africa, which prompted the World Health Organization (WHO) to declare a Public Health Emergency of International Concern (PHEIC). The company noted that current preparedness strategies are strain-specific, leaving gaps for less common Ebola species like BDBV, for which no broadly licensed vaccine exists.
In a statement released Monday, GeoVax highlighted its MVA-based hemorrhagic fever vaccine programs, which have shown preclinical protection against multiple filoviruses, including Ebola and Marburg. Key findings include single-dose protection against Zaire Ebola in non-human primates, protective efficacy against Sudan Ebola in guinea pigs and non-human primates, and significant survival protection against Marburg in rigorous challenge studies.
David A. Dodd, GeoVax's CEO, said, "These outbreaks collectively reinforce a growing reality: preparedness against one viral strain does not necessarily ensure preparedness against the next. The world is entering an era of continuous infectious disease emergence and re-emergence, where scalable vaccine platforms, diversified manufacturing capabilities, and flexible biodefense infrastructure will become increasingly important."
The company posits that its Modified Vaccinia Ankara (MVA) platform offers strategic advantages, including established safety profiles, flexibility for multiple antigens, rapid adaptation, and potential for multivalent single-dose vaccines. This is particularly relevant as the current outbreak exposes limitations in strain-specific approaches.
GeoVax is advancing GEO-MVA, its MVA-based candidate for mpox and smallpox, which is designed to support orthopox preparedness and bolster U.S. domestic MVA manufacturing. The pivotal Phase 3 immunobridging study, under an expedited EMA pathway, is scheduled to start in Q4 2026, with results expected within three months.
The broader implications extend beyond Ebola, as governments prioritize supply-chain resilience, domestic manufacturing, and flexible platforms. Dodd added, "Outbreaks involving Ebola, mpox, Marburg, hantavirus, and other emerging pathogens collectively reinforce the growing need for platform technologies capable of supporting rapid response against evolving threats."
GeoVax's comments come amid an increasingly complex infectious disease landscape, underscoring the importance of adaptable vaccine technologies for global biodefense. More information is available at www.geovax.com.